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Intragenic DOK7 deletion detected by
whole-genome sequencing in congenital
myasthenic syndromes
ABSTRACT
Objective: To identify the genetic cause in a patient affected by ptosis and exercise-induced mus-
cle weakness and diagnosed with congenital myasthenic syndromes (CMS) using whole-genome
sequencing (WGS).
Methods: Candidate gene screening andWGS analysis were performed in the case. Allele-specific
PCRwas subsequently performed to confirm the copy number variation (CNV) that was suspected
from the WGS results.
Results: In addition to the previously reported frameshift mutation c.1124_1127dup, an intra-
genic 6,261 bp deletion spanning from the 59 untranslated region to intron 2 of the DOK7 gene
was identified byWGS in the patient with CMS. The heterozygous deletion was suspected based
on reduced coverage on WGS and confirmed by allele-specific PCR. The breakpoints had micro-
homology and an inverted repeat, which may have led to the development of the deletion during
DNA replication.
Conclusions: We report a CMS case with identification of the breakpoints of the intragenic
DOK7 deletion using WGS analysis. This case illustrates that CNVs undetected by Sanger
sequencing may be identified by WGS and highlights their relevance in the molecular diagnosis
of a treatable neurologic condition such as CMS. Neurol Genet 2017;3:e152; doi: 10.1212/
NXG.0000000000000152
GLOSSARY
aCGH5 array comparative genomic hybridization; AChE 5 acetylcholinesterase; CMS 5 congenital myasthenic syndromes;
CNV 5 copy number variation; MLPA 5 multiplex ligation–dependent probe amplification; MuSK 5 muscle-specific tyrosine
kinase; NMJ 5 neuromuscular junction; WES 5 whole-exome sequencing; WGS 5 whole-genome sequencing.
Congenital myasthenic syndromes (CMS) are inherited disorders characterized by fatigable
muscle weakness with or without other associated signs or symptoms.1 They are caused by
mutations in genes expressed at the neuromuscular junction (NMJ). DOK7 is one of the
components of the NMJ and an activator of the muscle-specific tyrosine kinase (MuSK).2
Recessive mutations in DOK7 cause approximately 10% of the genetically diagnosed CMS
cases.1
CMS are heterogeneous diseases, and to date, more than 25 genes have been reported to be
causative. Consecutive single-gene screening has been routinely used as a diagnostic tool; how-
ever, next-generation sequencing allows the analysis of all these genes simultaneously to identify
the causative variant and obtain a genetic diagnosis. The efficacy of whole-exome sequencing
(WES) for the diagnosis of CMS cases has been reported,3,4 as well as its ability to identify
new causal genes.5,6 However, the limitation is that WES is designed to detect only protein-
coding regions and exon-intron boundaries of the genome.
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On the other hand, whole-genome
sequencing (WGS) allows the analysis of deep
intronic, intergenic, and other noncoding re-
gions. Furthermore, WGS allows to detect
copy number variations (CNVs), as coverage
is more homogeneous than that of WES.7
We present a CMS case in which a large
intragenic DOK7 deletion was identified by
WGS compound heterozygous to a known
exonic mutation.
METHODS DOK7 screening. DNA from the patient was
extracted from whole blood by standard methods. Screening of
hot-spot mutations was performed by Sanger sequencing, en-
compassing a region of;600 bp covering the previously reported
European founder mutation c.1124_1127dup.2 Subsequently,
full screening of coding regions and exon-intron boundaries of
the DOK7 gene was performed. Primer sequences are listed in
table e-1 at Neurology.org/ng. Annotation of the human DOK7
cDNA is according to the GenBank accession number NM_
173660.
Mutation analysis by WGS. WGS was performed by the Tru-
Seq PCR–free library preparation kit and HiSeqX v2 SBS kit
(Illumina, San Diego, CA) for 303 mean coverage on a HiSeqX
sequencer. Reads were mapped against hg19 reference genome
using the Burrows-Wheeler transform,8 and duplicates were
removed using Picard tools.9
Sequence variants were called using the Genome Analysis
Toolkit.10 WGS data were then analyzed using deCODE’s plat-
form (Clinical Sequence Miner; WuXi NextCODE, Cambridge,
MA). Rare variants were filtered by threshold of coverage ($8),
variant call ($2), and ratio of variant ($0.2) and allele frequency
of 1% in 1000 Genomes database.11
Sanger sequencing of large deletion. We amplified
DNA samples to identify the suspected intragenic deletion with
primers 59-CCCAGATGGTGCGCTTGCTCC-39and 59-
GCCCACCCCCTCACGCTCAG-39. The PCR protocol com-
prised 35 cycles and annealing temperature of 68°C using
HotStarTaq DNA polymerase with Q-Solution for the GC rich
region (QIAGEN, Düsseldorf, Germany).
Standard protocol approvals, registrations, and patient
consents. All human studies including genetic analysis were
approved by institutional review boards, and appropriate written
informed consent was obtained from all the patients and family
members.
RESULTS Clinical findings. The patient is a 39-year-
old Portuguese man who presented with bilateral
ptosis and exercise-induced muscle weakness. He had
no family history of muscle disease, and his motor
milestones in childhood were normal. He showed
mild ptosis from infancy and noticed mild lower limb
weakness at 13 years of age. He was admitted to
hospital for a month because of sudden severe gen-
eralized muscle weakness and worsening ptosis at 15
years of age. He has bilateral facial weakness and
winged scapula, and the clinical diagnosis of a neu-
romuscular transmission defect was confirmed by
neurophysiologic studies. EMG showed myopathic
changes on facial muscles. Repetitive nerve stimula-
tion showed a remarkable decremental response of
76% in proximal muscles. Both antiacetylcholine-
receptor and anti-MuSK antibodies were negative,
and immunosuppressive treatment was unsuccessful.
Acetylcholinesterase (AChE) inhibitor of pyr-
idostigmine up to 360 mg/d for 10 years had little
effect and was discontinued without clinical deterio-
ration after the trial of oral administration of salbu-
tamol which effected significantly. He has not
experienced severe muscle weakness for 5 years since
salbutamol was started.
DOK7 screening. Based on the limb-girdle clinical
presentation of the patient, a hot-spot region of
DOK7 was investigated as a first screening step.
Sanger sequencing revealed that the patient carried
the heterozygous c.1124_1127dup reported as
a founder mutation in European CMS patients.2 This
mutation was not present in the mother (DNA from
the father was unavailable). However, this single
heterozygous mutation does not explain DOK7-
CMS, which invariably shows autosomal recessive
inheritance. To identify a second heteroallelic DOK7
variant, the whole coding region and exon-intron
boundaries of the DOK7 gene were Sanger
sequenced, but no potentially pathogenic exonic or
splice site variants were found. The sample was
therefore subjected to WGS to try to identify other
mutations within the DOK7 gene or elsewhere in the
genome.
WGS analysis. As expected, applying a standard pipe-
line for variant filtering (minor allele frequency 1% in
coding region), the heterozygous c.1124_1127dup in
DOK7 was detected in the WGS data. This filtering
did not identify any other coding variants in known
CMS causal genes.
However, visual inspection of the sequencing
reads of the DOK7 gene for this patient revealed that
the read depth for exons 1 and 2 was lower than that
of neighboring regions and other control samples
(figure 1A). Furthermore, there were no heterozy-
gous variants within this region, indicating a run of
homozygosity or hemizygosity suggesting a single
copy region. Close inspection of the boundaries of
this region showed that in some instances, sections
of the sequencing reads did not match the reference
sequence. These reads were considered chimeric or
split reads, as the unmatched sequences did align to
a different region of the genome. Split reads are
indicative of structural variation. In fact, the 39 sec-
tion of the split reads of the proximal boundary
aligns to the 39end of the distal boundary, and vice
versa (figure 1B, red underline and red box). The
proximal and distal breakpoints lie approximately
6 kb away. These findings suggested that this patient
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has a heterozygous 6-kb deletion in DOK7 encom-
passing exons 1 and 2.
Identification and analysis of the intragenic DOK7
deletion.We performed PCR using a pair of primers
designed around 250 bp away from the presumed
breakpoints of the deletion, between the 59
untranslated region and intron 2. The expected
product of 488 bp was amplified in the DNA
samples of the patient, but not in control DNA
Figure 1 Whole-genome sequencing analysis and allele-specific PCR
(A) Both index case and his mother show reduced read depth (coverage) from exon 1 to deep intron 2 of theDOK7 gene (red arrow). Controls 1–4 correspond to
samples sequenced and analyzed through the same pipeline and without the diagnosis of congenital myasthenic syndromes. (B) Split reads were observed at
both presumed breakpoints. Nucleotides matching the reference sequence of DOK7 are highlighted in orange/blue. Single unmatched nucleotides are high-
lighted in yellow, and further unmatched sequences are not highlighted. The unmatched sequence (indicated with red/green underline) of the split reads of the
proximal breakpoint aligns to the reference sequence (indicated in green/red boxes) at the distal breakpoint, and vice versa. (C) The expected products amplified
by allele-specific PCR were identified in the index case and themother. (D) The junction of the breakpoint in the allele with the intragenic deletion was confirmed
by Sanger sequencing of the PCR product. Coverage and reads were drawn by the graphical user interface of Sequence Miner 5.21.1 (WuXi NextCODE).
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(figure 1C). The junction of the 2 breakpoints was
identified by Sanger sequencing of the PCR prod-
uct (figure 1D). The exact size of the deletion is
6,261 bp. The deletion was also detected by PCR
in the mother, who did not carry the
c.1124_1127dup mutation. We therefore con-
cluded that the CMS in the patient is caused by
the compound heterozygous mutations in DOK7.
Figure 2 Analysis of the breakpoints of the intragenic 6-kb deletion
(A) University of California Santa Cruz genome browser (genome.ucsc.edu/) view of the deleted region showing the Simple
Tandem Repeats track (based on Tandem Repeats Finder, TRF18) and the Repeating Elements track (based on Repeat-
Masker19). GT-rich repeat regions (green box) are seen around the distal breakpoint, and a G-rich region (green arrow) is
located near the proximal breakpoint. (B) The secondary DNA structure with the lowest delta G value was predicted by the
mfold tool (unafold.rna.albany.edu/?q5mfold) for the 800 and 200 bp regions around the proximal breakpoint. An enlarged
view of the breakpoint area highlighting the complementary nucleotides is also shown. The proximal breakpoint (indicated by
the red arrows) is at the boundary of a loop and a 12-bp inverted repeat that may cause stalling of DNA replication. It is
possible that deletion/duplication can occur if stalled replication resumes using an alternate location on the same chromo-
some. Red/blue/green bars represent hydrogen bonds between G-C/T-A/G-T.
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The 2 breakpoints of the deletion have a C-triplet
homology region, and the deleted region contains
a G-rich region and GT-rich repeat region (figure 2A).
In silico secondary structure analysis using the prediction
programmfold12 showed that the proximal breakpoint is
at the boundary of a loop and a 12-bp inverted repeat
(figure 2B). This may cause stalling of DNA replication
and subsequently result in chromosomal structural
changes including deletions, if replication resumes using
an alternate chromosomal location.
Screening of the intragenic deletion in a CMS cohort. To
identify carriers of single heterozygous mutations in
DOK7 (i.e., without a second rare variant within cod-
ing regions and exon-intron boundaries), we inter-
rogated our database of clinically diagnosed CMS
cases referred to us in the years 1996–2015. The total
number of patients with CMS was 577, of which 7
genetically unsolved cases had single frameshift mu-
tations in DOK7 (c.1124_1127dup in 6 cases and
c.1378dup in 1 case). These samples were amplified
using the deletion-specific pair of primers used to
detect the 6-kb deletion of the index family. All 7
samples were negative using this PCR method. This
does not exclude that they carry CNVs in DOK7
different from the one described in this study.
DISCUSSION We identified an intragenic DOK7
deletion in a patient with clinically diagnosed CMS.
Patients lacking a second heteroallelic mutation in
DOK7 were reported in a previous study.2 Moreover,
multiexon genomic deletions of RAPSN13 and
COLQ14 have also been identified as causative of
CMS. It is therefore conceivable that CNVs in
DOK7 may explain a proportion of cases assessed as
negative or inconclusive by conventional sequencing
analysis.
Our study shows the advantage of WGS analysis
and detailed interrogation for detecting CNVs, using
coverage and visual analysis of split reads. Tradition-
ally, multiplex ligation–dependent probe amplifica-
tion (MLPA) is considered the method of choice to
detect previously described CNVs, where kits are
available commercially. To identify new CNVs,
however, specific MLPA primers for each gene need
to be designed, rendering it expensive and time
consuming for testing a genetically heterogeneous
syndrome such as CMS. Array comparative genomic
hybridization (aCGH) is also a valuable method for
CNVs analysis; nevertheless, deletions/duplications
are not detectable by aCGH if they are shorter than
the spacing of the hybridization probes. In addition,
neither MLPA nor aCGH can detect single nucleo-
tide variants. Despite WES being widely used for
clinical sequencing, the library preparation step re-
sults in uneven coverage, which makes the estimation
of CNVs by read depth less reliable. This can be
overcome by the homogenous coverage of WGS, al-
lowing both the detection of single nucleotide as well
as CNV.
WGS analysis is still more expensive than WES
and Sanger sequencing. In addition, computational
tools need further improvement in sensitivity and
specificity to detect CNVs exhaustively.15 Taken
together, we believe that WGS is advantageous and
will become the method of choice for genetic diagno-
sis in rare, heterogeneous conditions such as CMS.
We suggest that previously unsolved cases or the
carriers of a single mutation in a causal gene are
especially suitable cases of CMS for WGS analysis.
The 6-kb deletion was not identified in other cases
tested by PCR, although it is inherited from the
mother, suggesting this is likely a private mutation.
However, it is possible that other CNVs in DOK7
underlie in CMS cases.
We also determined the breakpoints of the 6-kb
deletion, and analysis of the sequence and secondary
structure suggested that long inverted repeats might
cause the development of the deletion due to a stall
of replication, and microhomology might have played
a role in the repair process.16 Further documentation
of breakpoints and sequences would help understand
the mechanism for the development of CNVs.
Obtaining genetic diagnosis of CMS is very
important because the therapy varies depending on
the affected gene. Poor response to AChE inhibitors
is often observed in patients affected by limb-girdle
CMS due to DOK7 mutations. Salbutamol therapy
has now been started for the patient described in this
study, which has been reported of good response in
DOK7-CMS.17
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